AngioDynamics Launches New Midline Catheters

AngioDynamics ANGO today announced the launch of the BioFlo Midline catheter indicated for short-term intravenous therapies. The US Food and Drug Administration (FDA) granted 510(k) clearance for the BioFlo Midline catheter earlier this year. The BioFlo Midline catheter often delivers the same medications, including a variety of antibiotics, as a peripheral intravenous catheter (PIV.) However, Midlines can provide access for up to thirty days while PIVs typically need to be replaced every couple of days, usually due to performance failure. Midline catheters are ideal for patients who may require more than five days of intravenous therapy. "The BioFlo Midline catheter is a logical extension of the BioFlo product line, bringing the clinically relevant thrombus reduction properties to patients needing shorter term vascular access to deliver infusion therapies," said Chuck Greiner, AngioDynamics' Senior Vice President, Global Franchise Leader. "Its increased period of functionality improves patient satisfaction by lowering the number of needle sticks and interruptions to treatment. Similarly, it offers health care providers an expanded range of patient treatment options that help to increase staff efficiency See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsManagementPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!